CSL (OTCMKTS:CSLLY) Shares Gap Up – Still a Buy?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $29.91, but opened at $31.5430. CSL shares last traded at $31.00, with a volume of 1,192 shares changing hands.

Wall Street Analysts Forecast Growth

CSLLY has been the topic of a number of analyst reports. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Friday, August 7th. Jefferies Financial Group lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Five analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold”.

CSL Trading Up 2.2%

The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51. The firm has a fifty day simple moving average of $25.59 and a 200-day simple moving average of $23.63.

CSL Company Profile

CSL Limited (OTCMKTS:CSLLY) is an Australian biotechnology company that develops, manufactures and supplies medicines and vaccines. Founded in 1916 as the Commonwealth Serum Laboratories, the company was privatized in 1994 and has grown into a global provider of specialized biopharmaceutical products.

CSL’s principal businesses include CSL Behring, which develops plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders and other serious medical conditions; CSL Seqirus, which produces influenza and other vaccines; and CSL Vifor, which focuses on therapies for iron deficiency, kidney disease and related conditions.